Critical appraisal:Mandel JS, Church TR, Ederer F, Bond JH 1999 2
From Cancer Guidelines Wiki
Risk of bias assessment: Randomised Controlled Trial (Cochrane risk of bias tool)
Random sequence generation
Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.
- Randomisation process not described.
Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of or during, enrolment.
- Not described.
Describe all measures used, if any, to blind outcome assessors from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.
- Uncoded death certificates were obtained for all patients who died.
Incomplete outcome data
Describe the completeness of outcome data for each main outcome, including attrition and exlusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition/exclusions where reported, and any re-inclusions in analyses performed by the review authors.
- Missing data was present but not described. Follow-up for vital status through year 18 was complete for 88.8%, 89.1%, and 88.5% of annual, biennial, and control group participants, respectively.
Selective outcome reporting
State how the possibility of selective outcome reporting was examined by the review authors and what was found.
- Mortality described as outcome.
What was the risk of bias from selective outcome reporting? Assessments should be made for each main outcome (or class of outcomes).
Other sources of bias
Overall risk of bias
|Unclear risk of bias||Additional comments: Please replace this text and include any additional comments in regards to your risk of bias rating|
- Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999 Mar 3;91(5):434-7 Available from: http://www.ncbi.nlm.nih.gov/pubmed/10070942.
- Assigned to
- Topic area
- Guidelines:Colorectal cancer
- Clinical question
- Form:Quality appraisal rct-cochrane
- - Cancer related mortality; Mortality
- Clinical trial
Section below only relevant for Cancer Council Project Officer